With: Isis Pharmaceuticals
What: $1.9 billion deal
Scoop: Genzyme agreed to fork over up to $1.9 billion for rights to Isis Pharmaceutical's flagship program mipomersen, a cholesterol drug candidate. The company reportedly survived a bidding war for the drug that involved 10 companies. Mipomersen blocks a gene that opens the gate to cholesterol in the blood.